15. Amselem L, Diaz-Llopis M, Cervera E et al. (2008) [Intravitreal injection of bevacizumab (Avastin(R)) for retinal angiomatic proliferation.]. Arch Soc Esp Oftalmol 83:53-56
35. Bakri SJ, Pulido JS, Mccannel CA et al. (2007) Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab. Eye
42. Beer Pm, Wong Sj, Hammad Am et al. (2006) Vitreous levels of unbound bevacizumab and unbound vascular endothelial growth factor in two patients. Retina 26:871-876
47. Brantley Ma, Jr., Fang Am, King Jm et al. (2007) Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab. Ophthalmology 114:2168-2173
52. Chan Wm, Lai Ty, Liu Dt et al. (2007) Intravitreal bevacizumab (avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choriodopathy, or of idiopathic origin. Am J Ophthalmol 143:977-983
64. Cleary Ca, Jungkim S, Ravikumar K et al. (2008) Intravitreal bevacizumab in the treatment of neovascular age-related macular degeneration, 6- and 9-month results. Eye 22:82-86
75. Diaz-Llopis M, Amselem L, Cervera E et al. (2007) [Intravitreal injection of bevacizumab for pseudophakic cystoid macular edema resistant to steroids]. Arch Soc Esp Oftalmol 82:447-450
82. Feiner L, Barr Ee, Shui Yb et al. (2006) Safety of intravitreal injection of bevacizumab in rabbit eyes. Retina 26:882-888
87. Frimpong-Boateng A, Varde Ma, Rufer F et al. (2008) [Intravitreal administration of triamcinolone and bevacizumab for pigment epithelial detachment in conjunction with AMD]. Ophthalmolologe
100. Hoh Ae, Schaal Kb, Dithmar S (2007) [Central and branch retinal vein occlusion. Current strategies for treatment in Germany, Austria and Switzerland]. Ophthalmologe 104:290-294
110. Jaislse Gb, Ziemssen F, Petermeier K et al. (2006) [Bevacizumab for treatment of macular edema secondary to retinal vein occlusion.]. Ophthalmologe
144. Ladewig Ms, Ziemssen F, Jaisse G et al. (2006) [Intravitreal bevacizumab for neovascular age-related macular degeneration.]. Ophthalmologe
145. Ladewig Ms, Ziemssen F, Jaisse G et al. (2006) [Intravitreal bevacizumab for neovascular age-related macular degeneration]. Ophthalmologe 103:463-470


156. Moon Sj, Berger As, Tolentino Mj et al. (2007) Intravitreal bevacizumab for macular edema from idiopathic juxtafoveal retinal telangiectasis. Ophthalmic Surg Lasers Imaging 38:164-166


162. Niegel Mf, Schrage Nf, Christmann S et al. (2008) [Intravitreal bevacizumab for chronic central serous chorioretinopathy]. Ophthalmologe


177. Rich Rm, Rosenfeld Pj, Puliafito Ca et al. (2006) Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 26:495-511


190. Ruiz-Moreno Jm, Gomez-Ulla F, Montero Ja et al. (2007) Intravitreous bevacizumab to treat subfoveal choroidal neovascularization in highly myopic eyes: short-term results. Eye
197. Schaal Kb, Engler C, Schutt F et al. (2008) [Intravitreal anti-VEGF therapy with bevacizumab for neovascular AMD.]. Ophthalmologe
201. Scott Iu, Bressler Nm, Bressler Sb et al. (2008) Agreement between clinician and reading center gradings of diabetic retinopathy severity level at baseline in a phase 2 study of intravitreal bevacizumab for diabetic macular edema. Retina 28:36-40


224. Spitzer Ms, Yoeruek E, Sierra A et al. (2007) Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells. Graefes Arch Clin Exp Ophthalmol 245:1837-1842

